Edition:
United Kingdom

Novo Nordisk A/S (NOVOb.CO)

NOVOb.CO on Copenhagen Stock Exchange

329.50DKK
15 Dec 2017
Change (% chg)

kr.-6.90 (-2.05%)
Prev Close
kr.336.40
Open
kr.331.50
Day's High
kr.332.00
Day's Low
kr.325.80
Volume
5,325,531
Avg. Vol
3,156,389
52-wk High
kr.339.80
52-wk Low
kr.225.60

Select another date:

Fri, Dec 15 2017

Novo Nordisk wins EU panel's backing for key diabetes drug

COPENHAGEN Danish drugmaker Novo Nordisk came closer to winning European approval for diabetes drug Ozempic, its biggest growth prospect, when a European Medicines Agency (EMA) experts' panel issued a positive recommendation on Friday.

UPDATE 1-Novo Nordisk wins EU panel's backing for key diabetes drug

COPENHAGEN, Dec 15 Danish drugmaker Novo Nordisk came closer to winning European approval for diabetes drug Ozempic, its biggest growth prospect, when a European Medicines Agency (EMA) experts' panel issued a positive recommendation on Friday.

Novo Nordisk wins EU panel's backing for key diabetes drug

COPENHAGEN, Dec 14 Danish drugmaker Novo Nordisk came closer to winning European approval for diabetes drug Ozempic, its biggest growth prospect, when a European Medicines Agency (EMA) experts' panel issued a positive recommendation on Friday.

BRIEF-reMYND Enters Into License Agreement with Novo Nordisk​

* REMYND-UNDER AGREEMENT,CO COULD RECEIVE UP TO 350 MILLION EUROS IN RESEARCH AND MILESTONE PAYMENTS,PLUS ROYALTIES ON RESULTING NET SALES

BRIEF-Prime Therapeutics Says Co, Novo Nordisk To Establish Value-Based Contract For Type 2 Diabetes Drug Victoza

* PRIME THERAPEUTICS - CO, NOVO NORDISK TO ESTABLISH A VALUE-BASED CONTRACT FOR TYPE 2 DIABETES DRUG, VICTOZA Source text for Eikon: Further company coverage:

BRIEF-Novo Nordisk expects to launch new diabetes drug in Japan during H1 2018

Dec 6 NOVO NORDISK A/S CHIEF SCIENTIFIC OFFICER MADS KROGSGAARD THOMSEN MADE FOLLOWING COMMENTS DURING AN INVESTOR CALL FOLLOWING U.S. APPROVAL OF DIABETES DRUG OZEMPIC:

FDA approves Novo Nordisk diabetes drug Ozempic

The U.S. Food and Drug Administration on Tuesday approved Novo Nordisk A/S's diabetes drug Ozempic, setting the stage for a heated battle with Eli Lilly & Co's Trulicity.

UPDATE 3-U.S. FDA approves Novo Nordisk diabetes drug Ozempic

Dec 5 The U.S. Food and Drug Administration on Tuesday approved Novo Nordisk A/S's diabetes drug Ozempic, setting the stage for a heated battle with Eli Lilly & Co's Trulicity.

U.S. FDA approves Novo Nordisk diabetes drug Ozempic

Dec 5 The U.S. Food and Drug Administration on Tuesday approved Novo Nordisk A/S's diabetes drug Ozempic, setting the stage for a heated competitive battle with Eli Lilly & Co's Trulicity.

BRIEF-Novo Nordisk's Xultophy offers greater weight reductions than Iglarlixi

* XULTOPHY CAN DELIVER GREATER REDUCTIONS IN THE OVERALL BLOOD SUGAR LEVELS AND WEIGHT FOR PEOPLE WITH TYPE 2 DIABETES WHO ARE UNCONTROLLED ON BASAL INSULIN, COMPARED TO IGLARLIXI

Select another date: